Nishant C. Saxena net worth and biography

Nishant Saxena Biography and Net Worth

Mr. Saxena joined Corbus in May 2026. He has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he served as Chief Financial Officer at Jeune Aesthetics, Inc., a wholly owned subsidiary of Krystal Biotech, Inc. (NASDAQ: KRYS).

Previously, Mr. Saxena spent over 15 years at Evercore , most recently as a Managing Director in Evercore’s healthcare group.

What is Nishant C. Saxena's net worth?: The estimated net worth of Nishant C. Saxena is at least $695.40 thousand as of June 3rd, 2026. Saxena owns 75,300 shares of Corbus Pharmaceuticals stock worth more than $695,396 as of July 27th. This net worth estimate does not reflect any other investments that Saxena may own. Learn More about Nishant C. Saxena's net worth.
How do I contact Nishant C. Saxena?: The corporate mailing address for Saxena and other Corbus Pharmaceuticals executives is 500 River Ridge Drive, Norwood MA, 02062. Corbus Pharmaceuticals can also be reached via phone at (617) 963-0100 and via email at [email protected]. Learn More on Nishant C. Saxena's contact information.
Has Nishant C. Saxena been buying or selling shares of Corbus Pharmaceuticals?: Nishant C. Saxena has not been actively trading shares of Corbus Pharmaceuticals over the course of the past ninety days. Most recently, on Wednesday, June 3rd, Nishant C. Saxena bought 9,000 shares of Corbus Pharmaceuticals stock. The stock was acquired at an average cost of $7.58 per share, with a total value of $68,220.00. Following the completion of the transaction, the insider now directly owns 75,300 shares of the company's stock, valued at $570,774. Learn More on Nishant C. Saxena's trading history.
Who are Corbus Pharmaceuticals' active insiders?: Corbus Pharmaceuticals' insider roster includes Anne Altmeyer (Director), Yuval Cohen (CEO), Ian Hodgson (COO), John Jenkins (Director), Winston Kung (Director), and Nishant Saxena (Insider). Learn More on Corbus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Corbus Pharmaceuticals?: During the last twelve months, Corbus Pharmaceuticals insiders bought shares 2 times. They purchased a total of 13,500 shares worth more than $101,205.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 86,641 shares worth more than $1,177,188.36. The most recent insider tranaction occured on June, 10th when Director Winston Kung sold 2,026 shares worth more than $16,025.66. Insiders at Corbus Pharmaceuticals own 3.5% of the company. Learn More about insider trades at Corbus Pharmaceuticals.
Information on this page was last updated on 6/10/2026.

Nishant C. Saxena Insider Trading History at Corbus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/3/2026	Buy	9,000	$7.58	$68,220.00	75,300
6/2/2026	Buy	4,500	$7.33	$32,985.00	66,300

Nishant C. Saxena Buying and Selling Activity at Corbus Pharmaceuticals

Corbus Pharmaceuticals Company Overview

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Today's Range

Now: $9.08

$9.05

$9.54

50 Day Range

MA: $8.75

$7.38

$11.51

2 Week Range

Now: $9.08

$7.12

$20.56

Volume

363,235 shs

Average Volume

333,332 shs

Market Capitalization

$168.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.55